---
schema_version: "secwatch.filing_event.v1"
accession: "0001600620-23-000040"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2023-09-21T23:59:59+00:00"
generated_at: "2026-06-10T10:41:58.668533+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aurinia appoints founder Dr. Foster to board; enters cooperation agreement with MKT Capital

## Summary
- Dr. Robert T. Foster appointed to Board effective Sept 21, 2023; term expires at 2024 Annual Meeting.
- MKT Capital agrees to standstill until Oct 31, 2024 (with conditions) and 7% ownership cap.
- Dr. Foster receives standard non-employee director compensation: $45K annual cash, $200K annual equity, $340K new director grant.
- Dr. Foster retains 2% royalty on voclosporin licensee sales and 0.3% of direct net sales ($307,254 in FY2022).
- Press release notes Dr. Foster discovered voclosporin; strategic review remains ongoing.

## SEC filing metadata
- accession: 0001600620-23-000040
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2023-09-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000160062023000040/0001600620-23-000040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000160062023000040/auph-20230921.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001600620-23-000040
- JSON: https://secwatch.observer/filing/0001600620-23-000040.json
- Plain text: https://secwatch.observer/filing/0001600620-23-000040.txt

## Key facts
- Executive change
  Dr. Robert T. Foster was appointed as Board member at Aurinia Pharmaceuticals Inc..
  - Action: appointed
  - Role: Board member
  source text: In connection with the Cooperation Agreement, Dr. Foster was appointed to the Board, effective September 21, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600620/000160062023000040/0001600620-23-000040-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.